

2nd February 2026

ZYPINE ODT (Olanzapine) 10 mg Orosoluble Tablets
- Alternative Registered Foils

Dear Healthcare Professional,

We are writing to provide you with an important update regarding ZYPINE ODT (Olanzapine) 10 mg Orosoluble Tablets sponsored by Viatris Ltd.

To ensure continuous supply, a labelling exemption has been granted by Medsafe for Zypine ODT 10 mg Orosoluble Tablets to allow the supply of product manufactured for European markets into New Zealand for a short period.

The tablets produced for European markets are identical to the New Zealand product, with no difference in the formulation or appearance.

The blister strips from the European markets will be placed into the existing New Zealand-registered cartons. As the blister strips are from a different market, the following is of note:

- The foil text may appear in different languages, and/or
- The trade name printed on the foil may differ from 'Zypine ODT'.

Both New Zealand and European blisters may be distributed concurrently in the short term.

Images of the alternate blister foils are provided in the table overleaf.

Adverse Event Reporting & Medical Enquiries


Please report any suspected adverse events via email to Medinfo_anz@viatris.com. Alternatively, suspected adverse events may be reported to the Centre for Adverse Reactions Monitoring (CARM) online at <https://pophealth.my.site.com/carmreportnz/s/> or by email to CARMreport@health.govt.nz. Please direct any medical enquiries to Viatris or report any suspected adverse drug reactions to Viatris via telephone on 0800 168 169 or by email at medinfo_anz@viatris.com.

Yours sincerely,



Sue Lyn Lim
Senior Medical Affairs Specialist

Foil Overview

Existing Registered Foil	Alternative Registered Foils (temporary availability)
<p>Zypine ODT 10 mg</p> 	<p>Zypine ODT 10 mg</p> 

<p>Olanzapina Mylan 10 mg</p> 	<p>Olanzapina Mylan 10 mg</p> 
---	---